Albumin binding taxol

PreclinicalSmall molecule

Albumin binding taxol is one of 10 small molecule programs targeting Gastrointestinal Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal TumorsUnknown status

Gastrointestinal TumorsPreclinical

Unknown status

Competition

Competitive Landscape

12 competitors in Gastrointestinal Tumors

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Phase 2

1 2

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 3

BL-M24D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 4

BL-M09D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 5

BL-M02D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 6

GNC-077

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 7

BL-M08D1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 8

Bl-Arc002

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 9

Lutetium BL-ARC001

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 10

Albumin binding taxol

HHenan Cancer Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Neoadjuvant Treatment

NCT05918328

Clinical

Trials by Indication[1]

Gastrointestinal Tumors1 trial

Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol

Unknown status·HHenan Cancer Hospital·N/A·NCT03977077·100 enrolled

Neoadjuvant Treatment1 trial

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Recruiting·HHenan Cancer Hospital·Phase 2·NCT05918328·610 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Albumin binding taxol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albumin binding taxol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albumin binding taxol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHenan Cancer Hospital

Albumin binding taxol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Gastrointestinal Tumors1 trial

Neoadjuvant Treatment1 trial

References

Drug Info

Quick Facts

Related News